49 results on '"Kleinheinz, Andreas"'
Search Results
2. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study
- Author
-
Kocatürk, Emek, Salameh, Pascale, Sarac, Esra, Vera Ayala, Carolina E., Thomsen, Simon Francis, Zuberbier, Torsten, Ensina, Luis Felipe, Popov, Todor A., van Doorn, Martijn B.A., Giménez-Arnau, Ana Maria, Asero, Riccardo, Criado, Paulo Ricardo, Aarestrup, Fernando M., AbdulHameed Ansari, Zainab, Al Abri, Salma, Al-Ahmad, Mona, Al Hinai, Bushra, Allenova, Anastasiia, Al-Nesf, Maryam, Altrichter, Sabine, Arnaout, Rand, Bartosińska, Joanna, Bauer, Andrea, Bernstein, Jonathan A., Bizjak, Mojca, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Calvalcanti Dela Bianca Melo, Ana Caroline, Campinhos, Fernanda L., Carne, Emily, Purayil, Saleema Cherichi, Cherrez-Ojeda, Ivan, Chong-Neto, Herberto Jose, Christoff, George, Conlon, Niall, Jardim Criado, Roberta Fachini, Cvenkel, Klara, Damadoglu, Ebru, Danilycheva, Inna, Day, Cascia, de Montjoye, Laurence, Demir, Semra, Ferucci, Silvia Mariel, Fomina, Daria, Fukunaga, Atsushi, Garcia, Elizabeth, Gelincik, Asli, Göbel, Joe Hannah, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Gugala, Agata, Guillet, Carole, Kalyoncu, Ali Fuat, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Khoshkhui, Maryam, Kleinheinz, Andreas, Kolacinska-Flont, Marta, Kolkhir, Pavel, Košnik, Mitja, Krasowska, Dorota, Kumaran, Muthu Sendhil, Kuprys-Lipinska, Izabela, Kurowski, Marcin, Kuznetsova, Elizaveta V., Larenas-Linnemann, Désirée, Lebedkina, Marina S., Lee, Youngsoo, Makris, Michael, Gómez, René Maximiliano, Nasr, Iman, Neisinger, Sophia, Oda, Yoshiko, Kara, Rabia Öztaş, Palitot, Esther Bastos, Papapostolou, Niki, Salvador Parisi, Claudio Alberto, Pesque, David, Peter, Jonathan, Petkova, Elena, Ridge, Katie, Rudenko, Michael, Rutkowski, Krzysztof, Saini, Sarbjit S., Salman, Andac, Sanchez, Jorge, Şekerel, Bülent, Serdotetskova, Sofia A., Serpa, Faradiba S., Dikicier, Bahar Sevimli, Sidiropoulos, Nikitas, Sikora, Agnieszka, Sørensen, Jennifer Astrup, Soria, Angele, Kucuk, Ozlem Su, Thalappil, Sherin Rahim, Tomaszewska, Katarzyna, Tuncay, Gulseren, Unal, Derya, Valle, Solange, van Lindonk, Esmee, Vestergaard, Christian, Meshkova, Raisa Y., Vitchuk, Aleksandr, Xepapadaki, Paraskevi, Ye, Young-Min, Zalewska-Janowska, Anna, Zamlynski, Mateusz, and Maurer, Marcus
- Published
- 2023
- Full Text
- View/download PDF
3. 556 - A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany
- Author
-
Thaçi, Diamant, primary, Kleinheinz, Andreas, additional, Anastasiadou, Dimitra Maria, additional, Stinson, John, additional, and Armstrong, April W, additional
- Published
- 2024
- Full Text
- View/download PDF
4. Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food
- Author
-
Kraft, Magdalena, Dölle-Bierke, Sabine, Renaudin, Jean-Marie, Ruëff, Franziska, Scherer Hofmeier, Kathrin, Treudler, Regina, Pföhler, Claudia, Hawranek, Thomas, Poziomkowska-Gęsicka, Iwona, Jappe, Uta, Christoff, George, Müller, Sabine, Fernandez-Rivas, Montserrat, García, Blanca E., De Vicente Jiménez, Talía M., Cardona, Victoria, Kleinheinz, Andreas, Kreft, Burkhard, Bauer, Andrea, Wagner, Nicola, Wedi, Bettina, Wenzel, Markus, Bilò, Maria Beatrice, and Worm, Margitta
- Published
- 2021
- Full Text
- View/download PDF
5. Expert consensus on practical aspects in the treatment of chronic urticaria
- Author
-
Bauer, Andrea, Dickel, Heinrich, Jakob, Thilo, Kleinheinz, Andreas, Lippert, Undine, Metz, Martin, Schliemann, Sibylle, Schwichtenberg, Uwe, Staubach, Petra, Valesky, Eva, Wagner, Nicola, Wedi, Bettina, and Maurer, Marcus
- Published
- 2021
- Full Text
- View/download PDF
6. Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis.
- Author
-
Pinter, Andreas, Tsianakas, Athanasios, Eichner, Adina, for the ScaTAC study group, Paul, Carle, Passeron, Thierry, Reygagne, Pascal, Ruer, Mireille, Beissert, Stefan, Dirschka, Thomas, Gerdes, Sascha, Leitz, Nicolas, Pauser, Sylvia, Weirich, Oliver, Wildfeuer, Thomas, Kleinheinz, Andreas, Niesmann, Johannes, Crainic, Adrian, and Weber, Ridwan
- Published
- 2024
- Full Text
- View/download PDF
7. Hohe Rezidivrate des Eczema herpeticatum bei mittelschwerer bis schwerer atopischer Dermatitis – eine TREATgermany Registeranalyse.
- Author
-
Traidl, Stephan, Heinrich, Luise, Siegels, Doreen, Rösner, Lennart, Haufe, Eva, Harder, Inken, Abraham, Susanne, Ertner, Konstantin, Kleinheinz, Andreas, Schäkel, Knut, Wollenberg, Andreas, Effendy, Isaak, Quist, Sven, Asmussen, Andrea, Wildberger, Julia, Weisshaar, Elke, Wiemers, Franka, Brücher, Jens‐Joachim, Weidinger, Stephan, and Schmitt, Jochen
- Abstract
Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
8. High recurrence rate of eczema herpeticum in moderate/severe atopic dermatitis –TREATgermany registry analysis.
- Author
-
Traidl, Stephan, Heinrich, Luise, Siegels, Doreen, Rösner, Lennart, Haufe, Eva, Harder, Inken, Abraham, Susanne, Ertner, Konstantin, Kleinheinz, Andreas, Schäkel, Knut, Wollenberg, Andreas, Effendy, Isaak, Quist, Sven, Asmussen, Andrea, Wildberger, Julia, Weisshaar, Elke, Wiemers, Franka, Brücher, Jens‐Joachim, Weidinger, Stephan, and Schmitt, Jochen
- Abstract
Summary: Background: Eczema herpeticum (EH) is a disseminated skin infection caused by herpes simplex virus in atopic dermatitis (AD) patients. The frequency of EH and the clinical features of EH patients have not yet been investigated in a larger cohort. Methods: We sought to investigate the TREATgermany cohort, a multicenter, non‐interventional clinical registry of moderately to severely affected AD patients in Germany. Baseline characteristics of patients included between December 2017 and April 2021 were compared between patients without, single, and multiple EH. Results: Of the 893 patients, 195 (21.8%) had at least one EH. Of the 195 patients with EH, 107 had multiple EH (54.9%), representing 12.0% of the total study population. While there were no differences in demographic characteristics, previous treatment, and disease scores at enrollment (itch, IGA, oSCORAD, EASI), patients with EH had more frequent atopic comorbidities and sensitizations to house dust mite, food, and mold. Discussion: TREATgermany registry data suggest a high prevalence and recurrence rate of EH, while there appears to be no specific clinical phenotype, besides an increase in allergies, to identify EH patients in the daily routine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Itch, sleep loss, depressive symptoms, fatigue, and productivity loss in patients with moderate‐to‐severe atopic dermatitis: Analyses of TREATgermany registry data.
- Author
-
Birkner, Thomas, Siegels, Doreen, Heinrich, Luise, Haufe, Eva, Abraham, Susanne, Heratizadeh, Annice, Harder, Inken, Bell, Magnus, Fell, Isabell, Worm, Margitta, Handrick, Christiane, Effendy, Isaak, Asmussen, Andrea, Kleinheinz, Andreas, Homey, Bernhard, Sticherling, Michael, Hong‐Weldemann, Sung‐Hei, Augustin, Matthias, Weisshaar, Elke, and Schäkel, Knut
- Abstract
Summary: Background: TREATgermany is a multicenter registry including patients with moderate‐to‐severe atopic dermatitis (AD) from currently 74 study centers (university clinics, hospitals and practices) in Germany. As of August 31, 2021, 1,230 adult patients were enrolled. Methods: In TREATgermany, patients and physicians fill in questionnaires pertaining to symptoms, disease severity, quality of life, depressiveness, and fatigue. In particular, limitations in work performance are assessed using the Work Limitations Questionnaire (WLQ). To assess associations between occupational performance/work limitations and symptoms, correlations and regression models were calculated. Results: The examined sample of 228 employed patients reported an average of 6% at‐work productivity loss within the past two weeks prior to enrolment in the registry. The WLQ productivity loss score was moderately associated with itch (r = 0.32) and sleep loss (r = 0.39) and strongly associated with depressive symptoms (r = 0.68) and fatigue (r = 0.60). Conclusions: The analyses of the registry data show that moderate‐to‐severe atopic dermatitis has a negative impact on the work productivity of the patients. The analyses further point out the relevant associations between work productivity, depressive symptoms, and fatigue highlighting the disease burden caused by the psychological components of AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Juckreiz, Schlafstörungen, depressive Symptome, Fatigue und Einschränkungen der Arbeitsproduktivität bei Patienten mit moderater bis schwerer atopischer Dermatitis: Daten aus dem TREATgermany‐Register.
- Author
-
Birkner, Thomas, Siegels, Doreen, Heinrich, Luise, Haufe, Eva, Abraham, Susanne, Heratizadeh, Annice, Harder, Inken, Bell, Magnus, Fell, Isabell, Worm, Margitta, Handrick, Christiane, Effendy, Isaak, Asmussen, Andrea, Kleinheinz, Andreas, Homey, Bernhard, Sticherling, Michael, Hong‐Weldemann, Sung‐Hei, Augustin, Matthias, Weisshaar, Elke, and Schäkel, Knut
- Abstract
Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
11. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany
- Author
-
Weisshaar, Elke, primary, Bentz, Philipp, additional, Apfelbacher, Christian, additional, Haufe, Eva, additional, Heinrich, Luise, additional, Heratizadeh, Annice, additional, Abraham, Susanne, additional, Harder, Inken, additional, Kleinheinz, Andreas, additional, Wollenberg, Andreas, additional, Schäkel, Knut, additional, Wiemers, Franca, additional, Ertner, Julia, additional, Augustin, Matthias, additional, Wildberger, Julia, additional, Von Kiedrowski, Ralph, additional, Worm, Margitta, additional, Zink, Alexander, additional, Effendy, Isaak, additional, Asmussen, Andrea, additional, Pawlak, Mario, additional, Sticherling, Michael, additional, Hilgers, Melanie, additional, Handrick, Christiane, additional, Quist, Sven, additional, Schwarz, Beate, additional, Bell, Magnus, additional, Staubach-Renz, Petra, additional, Hong-Weldemann, Sung-Hei, additional, Homey, Bernhard, additional, Brücher, Jens-Joachim, additional, Weidinger, Stephan, additional, Werfel, Thomas, additional, and Schmitt, Jochen, additional
- Published
- 2023
- Full Text
- View/download PDF
12. Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany
- Author
-
Weisshaar, Elke, Bentz, Philipp, Haufe, Eva, Heinrich, Luise, Apfelbacher, Christian, Heratizadeh, Annice, Abraham, Susanne, Harder, Inken, Kleinheinz, Andreas, Wollenberg, Andreas, Schäkel, Knut, Wiemers, Franca, Ertner, Konstantin, Augustin, Matthias, Wildberger, Julia, von Kiedrowski, Ralph, Worm, Margitta, Zink, Alexander, Effendy, Isaak, Asmussen, Andrea, Pawlak, Mario, Sticherling, Michael, Hilgers, Melanie, Handrick, Christiane, Quist, Sven, Schwarz, Beate, Bell, Magnus, Staubach-Renz, Petra, Hong-Weldemann, Su-Hei, Homey, Bernhard, Bruecher, Jens, Weidinger, Stephan, Werfel, Thomas, and Schmitt, Jochen
- Subjects
Dermatology - Published
- 2023
13. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis.
- Author
-
Hartmann, Jan, Moitinho‐Silva, Lucas, Sander, Nicole, Harder, Inken, Häsler, Robert, Rodriguez, Elke, Haufe, Eva, Kleinheinz, Andreas, Abraham, Susanne, Heratizadeh, Annice, Weisshaar, Elke, Schäkel, Knut, Handrick, Christiane, Augustin, Matthias, Wollenberg, Andreas, Staubach‐Renz, Petra, Ertner, Konstantin, Sticherling, Michael, Schwarz, Beate, and Quist, Sven
- Subjects
ATOPIC dermatitis ,DUPILUMAB ,CYCLOSPORINE ,BOTANY ,BACTERIAL diversity ,ECZEMA - Abstract
Background: Atopic dermatitis (AD) patients display an altered skin microbiome which may not only be an indicator but also a driver of inflammation. We aimed to investigate associations among AD patients' skin microbiome, clinical data, and response to systemic therapy in patients of the TREATgermany registry. Methods: Skin swabs of 157 patients were profiled with 16S rRNA gene amplicon sequencing before and after 3 months of treatment with dupilumab or cyclosporine. For comparison, 16s microbiome data from 258 population‐based healthy controls were used. Disease severity was assessed using established instruments such as the Eczema Area and Severity Index (EASI). Results: We confirmed the previously shown correlation of Staphylococcus aureus abundance and bacterial alpha diversity with AD severity as measured by EASI. Therapy with Dupilumab shifted the bacterial community toward the pattern seen in healthy controls. The relative abundance of Staphylococci and in particular S. aureus significantly decreased on both lesional and non‐lesional skin, whereas the abundance of Staphylococcus hominis increased. These changes were largely independent from the degree of clinical improvement and were not observed for cyclosporine. Conclusions: Systemic treatment with dupilumab but not cyclosporine tends to restore a healthy skin microbiome largely independent of the clinical response indicating potential effects of IL‐4RA blockade on the microbiome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Perception of the coronavirus pandemic by patients with atopic dermatitis – Results from the TREATgermany registry
- Author
-
Helmert, Claudia, Siegels, Doreen, Haufe, Eva, Abraham, Susanne, Heratizadeh, Annice, Kleinheinz, Andreas, Harder, Inken, Schäkel, Knut, Effendy, Isaak, Wollenberg, Andreas, Sticherling, Michael, Stahl, Maren, Worm, Margitta, Schwichtenberg, Uwe, Schwarz, Beate, Rossbacher, Jens, Buck, Philipp Marcel, Schenck, Florian, Werfel, Thomas, Weidinger, Stephan, and Schmitt, Jochen
- Subjects
Coronavirus ,Male ,Quality of Life ,Humans ,Female ,Perception ,Registries ,Dermatology ,Pandemics ,Severity of Illness Index ,Dermatitis, Atopic - Abstract
TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD.A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life-Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t-tests, analyses of variance and correlations were evaluated, controlled for sex and age.58 % (n = 233) of the included 400 registry patients reported high burden scores caused by the coronavirus pandemic, regardless of an actual infection. Men showed significantly higher burden scores than women, and younger than older respondents (both P = 0.03). There were no differences in burden scores related to the physician's assessment of disease severity. However, patients with higher quality of life impairments and higher disease severity perceived the burden of the coronavirus pandemic as less severe (DLQI P = 0.019, PGA P = 0.044).Our data show that registry patients considered the coronavirus pandemic as a life-changing event and perceived the burden differently. This should be taken into account in the treatment of patients with moderate to severe AD as well as in further studies.
- Published
- 2021
15. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry
- Author
-
Stölzl, Dora, Sander, Nicole, Heratizadeh, Annice, Haufe, Eva, Harder, Inken, Abraham, Susanne, Heinrich, Luise, Kleinheinz, Andreas, Wollenberg, Andreas, Weisshaar, Elke, Schäkel, Knut, Ertner, Konstantin, Wiemers, Franca, Wildberger, Julia, Worm, Margitta, von Kiedrowski, Ralph, Effendy, Isaak, Asmussen, Andrea, Augustin, Matthias, Pawlak, Mario, Sticherling, Michael, Zink, Alexander, Hilgers, Melanie, Handrick, Christiane, Quist, Sven R., Schwarz, Beate, Staubach-Renz, Petra, Bell, Magnus, Hong-Weldemann, Sun-Hei, Homey, Bernhard, Brücher, Jens-Joachim, Schmitt, Jochen, Werfel, Thomas, and Weidinger, Stephan
- Subjects
Treatment Outcome ,Humans ,Dermatology ,Registries ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index - Abstract
This interim analysis from the atopic dermatitis registry TREATgermany shows robust long-term efficacy, favourable safety and high persistence of dupilumab under real life conditions.
- Published
- 2022
16. Histopathological risk factors for malignancy in dermatomyositis
- Author
-
Pruessmann, Wiebke, primary, Kleinheinz, Andreas, additional, Zillikens, Detlef, additional, and Rose, Christian, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis
- Author
-
Möbus, Lena, primary, Rodriguez, Elke, additional, Harder, Inken, additional, Boraczynski, Nicole, additional, Szymczak, Silke, additional, Hübenthal, Matthias, additional, Stölzl, Dora, additional, Gerdes, Sascha, additional, Kleinheinz, Andreas, additional, Abraham, Susanne, additional, Heratizadeh, Annice, additional, Handrick, Christiane, additional, Haufe, Eva, additional, Werfel, Thomas, additional, Schmitt, Jochen, additional, and Weidinger, Stephan, additional
- Published
- 2022
- Full Text
- View/download PDF
18. Wahrnehmung der Corona-Pandemie durch Neurodermitispatienten - Ergebnisse aus dem Neurodermitisregister TREATgermany
- Author
-
Helmert, Claudia, Siegels, Doreen, Haufe, Eva, Abraham, Susanne, Heratizadeh, Annice, Kleinheinz, Andreas, Harder, Inken, Schäkel, Knut, Effendy, Isaak, Wollenberg, Andreas, Sticherling, Michael, Stahl, Maren, Worm, Margitta, Schwichtenberg, Uwe, Schwarz, Beate, Rossbacher, Jens, Buck, Philipp Marcel, Schenck, Florian, Werfel, Thomas, Weidinger, Stephan, and Schmitt, Jochen
- Subjects
Dermatology - Abstract
Hintergrund: TREATgermany, ein Register für Patienten mit moderater bis schwerer atopischer Dermatitis (AD), etablierte im Frühjahr 2020 einen zusätzlichen Fragebogen, um Auswirkungen der Corona-Pandemie auf die Lebenssituation von Patienten mit AD zu untersuchen. Methodik: Anhand eines Fragebogens wurden allgemeine Informationen zum Erleben der Corona-Pandemie und, unter Anwendung des Inventars lebensverändernder Ereignisse, die resultierenden Belastungen der Patienten untersucht. Zur Analyse möglicher Assoziationen zwischen Erkrankungsschwere (EASI-Score, oSCORAD, IGA, PGA, POEM), Lebensqualität (DLQI) und persönlichen Belastungen wurden t-Tests, Varianzanalysen und Korrelationen kontrolliert nach Geschlecht und Alter genutzt. Ergebnisse: 58 % (N = 233) der einbezogenen 400 Registerpatienten berichteten eine hohe Belastung durch die Corona-Pandemie, unabhängig von einer tatsächlichen Infektion. Männer zeigten signifikant höhere Belastungswerte als Frauen sowie jüngere höhere als ältere Befragte (jeweils P = 0,03). Es gab keine Unterschiede der Belastungswerte bezogen auf die ärztliche Beurteilung der Erkrankungsschwere. Jedoch reflektierten Patienten mit höherer Einschränkung der Lebensqualität und ausgeprägterer Krankheitslast die Belastung durch die Corona-Pandemie als weniger hoch (DLQI P = 0,019, PGA P = 0,044). Schlussfolgerungen: Es konnte gezeigt werden, dass die Registerpatienten die Corona-Pandemie als lebensveränderndes Ereignis reflektieren und die Belastung unterschiedlich wahrnehmen. Dies sollte sowohl bei der Behandlung von Patienten mit moderater bis schwerer AD berücksichtigt als auch in weiterführenden Untersuchungen vertieft werden., BACKGROUND: TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD.; MATERIAL AND METHODS: A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life-Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t-tests, analyses of variance and correlations were evaluated, controlled for sex and age.; RESULTS: 58% (n=233) of the included 400 registry patients reported high burden scores caused by the coronavirus pandemic, regardless of an actual infection. Men showed significantly higher burden scores than women, and younger than older respondents (both P=0.03). There were no differences in burden scores related to the physician's assessment of disease severity. However, patients with higher quality of life impairments and higher disease severity perceived the burden of the coronavirus pandemic as less severe (DLQI P=0.019, PGA P=0.044).; CONCLUSIONS: Our data show that registry patients considered the coronavirus pandemic as a life-changing event and perceived the burden differently. This should be taken into account in the treatment of patients with moderate to severe AD as well as in further studies. © 2021 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
- Published
- 2022
19. BJD_2022_1124_SUPPLEMENT.docx
- Author
-
Stölzl, Dora, Sander, Nicole, Heratizadeh, Annice, Haufe, Eva, Harder, Inken, Abraham, Susanne, Heinrich, Luise, Kleinheinz, Andreas, Wollenberg, Andreas, Weisshaar, Elke, Schäkel, Kurt, Ertner, Konstantin, Wiemers, Franca, Wildberger, Julia, Worm, Margitta, Kiedrowski, Ralph von, Effendy, Isaak, Asmussen, Andrea, Augustin, Matthias, Pawlak, Mario, Sticherling, Michael, Zink, Andreas, Hilgers, Melanie, Handrick, Christiane, Quist, Sven, Schwarz, Beate, Staubach-Renz, Petra, Bell, Martin, Hong-Weldemann, Sung-Hei, Homey, Bernhard, Brücher, Jens-Joachim, Schmitt, Jochen, Werfel, Thomas, and Weidinger, Stephan
- Abstract
Real-World data on effectiveness, safety and drug survival of dupilumab: An analysis from the TREATgermany registry. Table 1: Effectiveness outcomes of dupilumab and cyclosporine to month 3, 6 and 12
- Published
- 2022
- Full Text
- View/download PDF
20. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany
- Author
-
Schmitt, Jochen, Abraham, Susanne, Trautmann, Freya, Stephan, Victoria, FölsterHolst, Regina, Homey, Bernhard, Bieber, Thomas, Novak, Natalija, Sticherling, Michael, Augustin, Matthias, Kleinheinz, Andreas, Elsner, Peter, Weidinger, Stephan, and Werfel, Thomas
- Published
- 2017
- Full Text
- View/download PDF
21. Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitis‐Registers TREATgermany
- Author
-
Schmitt, Jochen, Abraham, Susanne, Trautmann, Freya, Stephan, Victoria, FölsterHolst, Regina, Homey, Bernhard, Bieber, Thomas, Novak, Natalija, Sticherling, Michael, Augustin, Matthias, Kleinheinz, Andreas, Elsner, Peter, Weidinger, Stephan, and Werfel, Thomas
- Published
- 2017
- Full Text
- View/download PDF
22. S3-Guideline on allergy prevention: 2014 update: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Society for Pediatric and Adolescent Medicine (DGKJ)
- Author
-
Schäfer, Torsten, Bauer, Carl-Peter, Beyer, Kirsten, Bufe, Albrecht, Friedrichs, Frank, Gieler, Uwe, Gronke, Gerald, Hamelmann, Eckard, Hellermann, Mechthild, Kleinheinz, Andreas, Klimek, Ludger, Koletzko, Sibylle, Kopp, Matthias, Lau, Susanne, Müsken, Horst, Reese, Imke, Schmidt, Sabine, Schnadt, Sabine, Sitter, Helmut, Strömer, Klaus, Vagts, Jennifer, Vogelberg, Christian, Wahn, Ulrich, Werfel, Thomas, Worm, Margitta, and Muche-Borowski, Cathleen
- Published
- 2014
- Full Text
- View/download PDF
23. The german AD Registry Treatgermany: Results from an interim data analysis on baseline charesteristics, comorbidities and treatment history
- Author
-
Heratizadeh, Annice, Haufe, Eva, Stölzl, Dora, Abraham, Susanne, Heinrich, Luise, Kleinheinz, Andreas, Wollenberg, Andreas, Weisshaar, Elke, Augustin, Matthias, Wiemers, Franca, Zink, Alexander, von Kiedrowski, Ralph, Hilgers, Melanie, Worm, Margitta, Pawlak, Mario, Sticherling, Michael, Fell, Isabel, Handrick, Christian, Schäkel, Knut, Staubach-Renz, Petra, Asmussen, Andrea, Schwarz, Beate, Bell, Magnus, Effendy, Isaak, Bieber, Thomas, Homey, Bernhard, Gerlach, Beatrice, Tchitcherina, Ekaterina, Stahl, Maren, Schwichtenberg, Uwe, Rossbacher, Jens, Buck, Philipp, Mempel, Martin, Beissert, Stefan, Biedermann, Tilo, Weidinger, Stephan, Schmitt, Jochen, and Werfel, Thomas
- Published
- 2021
24. Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis
- Author
-
Möbus, Lena, primary, Rodriguez, Elke, additional, Harder, Inken, additional, Schwarz, Agatha, additional, Wehkamp, Ulrike, additional, Stölzl, Dora, additional, Boraczynski, Nicole, additional, Gerdes, Sascha, additional, Litman, Thomas, additional, Kleinheinz, Andreas, additional, Abraham, Susanne, additional, Heratizadeh, Annice, additional, Handrick, Christiane, additional, Haufe, Eva, additional, Schmitt, Jochen, additional, Werfel, Thomas, additional, and Weidinger, Stephan, additional
- Published
- 2021
- Full Text
- View/download PDF
25. A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany.
- Author
-
Thaçi, Diamant, Kleinheinz, Andreas, Anastasiadou, Dimitra Maria, Stinson, John, and Armstrong, April W.
- Subjects
- *
ATOPIC dermatitis , *PATIENT compliance , *ECZEMA , *COHORT analysis , *MONOCLONAL antibodies , *DUPILUMAB - Abstract
Introduction/Background Tralokinumab is a high-affinity, fully human IgG4 monoclonal antibody that specifically targets interleukin-13, a key driver of atopic dermatitis (AD) disease progression. Clinical trials have shown that tralokinumab is efficacious in patients with moderate-to-severe AD and has a favorable safety profile, including a low frequency of adverse events such as conjunctivitis. Management of patients in routine clinical practice differs from those enrolled in clinical trials due to strict protocol criteria, and there is a lack of clinical data on tralokinumab use in the real-world setting. Objectives: TRACE is a real-world study in patients with AD, aiming to better understand the effectiveness, safety, and clinical use of tralokinumab in daily practice. Here, we describe baseline characteristics from the first patients enrolled into TRACE in Germany. Methods: TRACE is an observational, prospective, single-cohort study of adult patients with moderate-to-severe AD who are treated with tralokinumab, according to national approved labels. Eleven countries are participating in the study across Europe, North America and the Middle East. The primary objective is to assess changes in clinical signs and symptoms of AD in tralokinumab-treated patients. Secondary objectives are to investigate safety, quality of life, patient-reported outcomes and treatment adherence, among others. Results: Of the first 100 patients initiated on tralokinumab, the mean age (standard deviation [SD]) was 44.7 years (17.9) and 58% were male. Most patients had moderate-to-severe AD with a mean Investigator's Global Assessment (IGA) score of 3.5 (SD 0.7) and mean Eczema Area and Severity Index (EASI) of 22.5 (SD 12.9). Patients reported heavy symptomatic burden of disease; the mean eczema-related sleep numerical rating scale (NRS) was 5.6 (SD 2.9) and mean worst daily pruritus NRS was 6.2 (SD 2.7). Patients also reported a substantial impact on quality of life, demonstrated by a mean Dermatology Life Quality Index of 15.6 (SD 6.9). Overall, 79 patients were biologic-naïve and 19 were biologic-experienced (data missing; n=2). All biologic-experienced patients were previously treated with dupilumab, of whom most experienced one or more treatment failures. Reasons for switching from dupilumab included lack or loss of effectiveness, and adverse events, which most commonly included conjunctivitis. Conclusions: Initial findings showed that most adult patients with moderate-to-severe AD who were treated with tralokinumab were biologic-naïve, indicating tralokinumab is prescribed as firstline systemic treatment in real-world clinical practice, in line with European Dermatology Forum guidelines. The main reasons for switching from dupilumab were lack or loss of effectiveness, and adverse events, such as conjunctivitis, indicating the need for alternative biologic treatments such as tralokinumab. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Expertenkonsensus zu praxisrelevanten Aspekten bei der Behandlung der chronischen Urtikaria
- Author
-
Bauer, Andrea, primary, Dickel, Heinrich, additional, Jakob, Thilo, additional, Kleinheinz, Andreas, additional, Lippert, Undine, additional, Metz, Martin, additional, Schliemann, Sibylle, additional, Schwichtenberg, Uwe, additional, Staubach, Petra, additional, Valesky, Eva, additional, Wagner, Nicola, additional, Wedi, Bettina, additional, and Maurer, Marcus, additional
- Published
- 2021
- Full Text
- View/download PDF
27. Atopic dermatitis displays stable and dynamic skin transcriptome signatures
- Author
-
Möbus, Lena, primary, Rodriguez, Elke, additional, Harder, Inken, additional, Stölzl, Dora, additional, Boraczynski, Nicole, additional, Gerdes, Sascha, additional, Kleinheinz, Andreas, additional, Abraham, Susanne, additional, Heratizadeh, Annice, additional, Handrick, Christiane, additional, Haufe, Eva, additional, Werfel, Thomas, additional, Schmitt, Jochen, additional, and Weidinger, Stephan, additional
- Published
- 2021
- Full Text
- View/download PDF
28. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Maurer, Marcus, Aberer, Werner, Agondi, Rosana, Al���Ahmad, Mona, Al���Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Ayg��ren���P��rs��n, Emel, Banerji, Aleena, Bauer, Andrea, Ben���Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A., Betschel, Stephen, Bindslev���Jensen, Carsten, Bizjak, Mojca, Boccon���Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby���Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, R��gis A., Cancian, Mauro, Cherrez���Ojeda, Ivan, Cohn, Danny M., Costa, C��lia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du���Thanh, Aur��lie, Ensina, Luis Felipe, Erta��, Rag��p, Fabiani, Jos�� E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras���Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Asli, Gim��nez���Arnau, Ana, Godse, Kiran, Gompels, Mark, Gon��alo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S., Guidos���Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye���Ryun, Kaplan, Allen, Kasperska���Zaj��c, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kocat��rk, Emek, Ko��nik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jos�� Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbr��n, Alejandro, Marsland, Alexander, Martinez���Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako, Ohsawa, Isao, ��zyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pf��tzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, R��ckmann���Helmbach, Heike, Rudenko, Michael, Salman, Anda��, Sanchez���Borges, Mario, Schmid���Grendelmeier, Peter, Serpa, Faradiba S., Serra���Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Ang��le, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, Doorn, Martijn, Varga, Lilian, V��zquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber���Chrysochoou, Christina, Ye, Young���Min, Zalewska���Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., and Castaldo, Anthony
- Subjects
urticaria ,center ,angioedema ,excellence ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit ,management - Published
- 2020
29. Definition, aims, and implementation of GA²LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Maurer, Marcus, Aberer, Werner, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygören-Pürsü, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A., Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Régis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Célia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurélie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, José E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Asli, Giménez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Gonçalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S., Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zając, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kocatürk, Emek, Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, José Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbrán, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfützner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Röckmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angèle, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vázquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., and Castaldo, Anthony
- Subjects
Medizin - Published
- 2020
30. Definition, aims, and implementation of GA(2)LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Maurer, Marcus Werner, Aberer Agondi, Rosana Al-Ahmad, Mona and Al-Nesf, Maryam Ali Ansotegui, Ignacio Arnaout, Rand and Arruda, Luisa Karla Asero, Riccardo Aygoeren-Puersue, Emel and Banerji, Aleena Bauer, Andrea Ben-Shoshan, Moshe Berardi, Alejandro Bernstein, Jonathan A. Betschel, Stephen and Bindslev-Jensen, Carsten Bizjak, Mojca Boccon-Gibod, Isabelle and Bork, Konrad Bouillet, Laurence Boysen, Henrik Balle and Brodszki, Nicholas Broesby-Olsen, Sigurd Busse, Paula and Buttgereit, Thomas Bygum, Anette Caballero, Teresa Campos, Regis A. Cancian, Mauro Cherrez-Ojeda, Ivan Cohn, Danny M. and Costa, Celia Craig, Timothy Criado, Paulo Ricardo and Criado, Roberta F. Csuka, Dorottya Dissemond, Joachim and Du-Thanh, Aurelie Ensina, Luis Felipe Ertas, Ragip Fabiani, Jose E. Fantini, Claudio Farkas, Henriette Ferrucci, Silvia Mariel Figueras-Nart, Ignasi Fili, Natalia L. Fomina, Daria and Fukunaga, Atsushi Gelincik, Asli Gimenez-Arnau, Ana and Godse, Kiran Gompels, Mark Goncalo, Margarida Gotua, Maia and Gower, Richard Grumach, Anete S. Guidos-Fogelbach, Guillermo and Hide, Michihiro Ilina, Natalia Inomata, Naoko Jakob, Thilo Josviack, Dario O. Kang, Hye-Ryun Kaplan, Allen and Kasperska-Zajac, Alicja Katelaris, Constance Kessel, Aharon and Kleinheinz, Andreas Kocaturk, Emek Kosnik, Mitja Krasowska, Dorota Kulthanan, Kanokvalai Kumaran, M. Sendhil Larco Sousa, Jose Ignacio Longhurst, Hilary J. Lumry, William and MacGinnitie, Andrew Magerl, Markus Makris, Michael P. and Malbran, Alejandro Marsland, Alexander Martinez-Saguer, Inmaculada Medina, Iris V. Meshkova, Raisa Metz, Martin and Nasr, Iman Nicolay, Jan Nishigori, Chikako Ohsawa, Isao and Ozyurt, Kemal Papadopoulos, Nikolaos G. Parisi, Claudio A. S. and Peter, Jonathan Grant Pfuetzner, Wolfgang Popov, Todor and Prior, Nieves Ramon, German D. Reich, Adam Reshef, Avner and Riedl, Marc A. Ritchie, Bruce Rockmann-Helmbach, Heike and Rudenko, Michael Salman, Andac Sanchez-Borges, Mario and Schmid-Grendelmeier, Peter Serpa, Faradiba S. Serra-Baldrich, Esther Sheikh, Farrukh R. Smith, William Soria, Angele and Staubach, Petra Steiner, Urs C. Stobiecki, Marcin Sussman, Gordon Tagka, Anna Thomsen, Simon Francis Treudler, Regina and Valle, Solange van Doorn, Martijn Varga, Lilian Vazquez, Daniel O. Wagner, Nicola Wang, Liangchun Weber-Chrysochoou, Christina Ye, Young-Min Zalewska-Janowska, Anna Zanichelli, Andrea Zhao, Zuotao Zhi, Yuxiang Zuberbier, Torsten and Zwiener, Ricardo D. Castaldo, Anthony
- Published
- 2020
31. Einsatz des ersten Biologikums in der Therapie des atopischen Ekzems unter real-life-Bedingungen: Ergebnisse des Deutschen Neurodermitis-Registers TREATgermany
- Author
-
Abraham, Susanne, Haufe, Eva, Harder, Inken, Heratizadeh, Annice, Kleinheinz, Andreas, Wollenberg, Andreas, Weisshaar, Elke, Wiemers, Franca, Augustin, Matthias, Zink, Alexander, von Kiedrowski, Ralph, Worm, Margitta, Hilgers, Melanie, Pawlak, Mario, Fell, Isabel, Schäkel, Knut, Handrick, Christiane, Sticherling, Michael, Staubach-Renz, Petra, Asmussen, Andrea, Bell, Magnus, Schwarz, Beate, Beissert, Stefan, Biedermann, Tilo, Weidinger, Stephan, and Schmitt, Jochen
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Hintergrund: Die Zulassung des ersten Biologikums zur Therapie der mittelschweren bis schweren atopischen Dermatitis (AD) eröffnet eine neue Therapieoption für Patienten, bei denen die Erkrankungsschübe und die Einschränkungen der gesundheitsbezogenen Lebensqualität durch äußerliche[zum vollständigen Text gelangen Sie über die oben angegebene URL], 18. Deutscher Kongress für Versorgungsforschung (DKVF)
- Published
- 2019
- Full Text
- View/download PDF
32. Anaphylactic reactions to pomegranate: identification and characterization of eliciting IgE-reactive components
- Author
-
Petersen Arnd, Kleinheinz Andreas, and Jappe Uta
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Published
- 2011
- Full Text
- View/download PDF
33. Perception of the coronavirus pandemic by patients with atopic dermatitis – Results from the TREATgermany registry.
- Author
-
Helmert, Claudia, Siegels, Doreen, Haufe, Eva, Abraham, Susanne, Heratizadeh, Annice, Kleinheinz, Andreas, Harder, Inken, Schäkel, Knut, Effendy, Isaak, Wollenberg, Andreas, Sticherling, Michael, Stahl, Maren, Worm, Margitta, Schwichtenberg, Uwe, Schwarz, Beate, Rossbacher, Jens, Buck, Philipp Marcel, Schenck, Florian, Werfel, Thomas, and Weidinger, Stephan
- Abstract
Summary: Background: TREATgermany, a registry for patients with moderate to severe atopic dermatitis (AD), established an additional questionnaire in spring 2020 to investigate the effects of the coronavirus pandemic on the daily life of patients with AD. Material and Methods: A questionnaire was used to analyze general information regarding a patient's experience of the coronavirus pandemic and, using the Inventory of Life‐Changing Events, the resulting personal burden. To analyze possible associations between disease severity (EASI score, oSCORAD, IGA, PGA, POEM), quality of life (DLQI) and personal burden, t‐tests, analyses of variance and correlations were evaluated, controlled for sex and age. Results: 58 % (n = 233) of the included 400 registry patients reported high burden scores caused by the coronavirus pandemic, regardless of an actual infection. Men showed significantly higher burden scores than women, and younger than older respondents (both P = 0.03). There were no differences in burden scores related to the physician's assessment of disease severity. However, patients with higher quality of life impairments and higher disease severity perceived the burden of the coronavirus pandemic as less severe (DLQI P = 0.019, PGA P = 0.044). Conclusions: Our data show that registry patients considered the coronavirus pandemic as a life‐changing event and perceived the burden differently. This should be taken into account in the treatment of patients with moderate to severe AD as well as in further studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Definition, aims, and implementation of GA 2 LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Maurer, Marcus, primary, Aberer, Werner, additional, Agondi, Rosana, additional, Al‐Ahmad, Mona, additional, Al‐Nesf, Maryam Ali, additional, Ansotegui, Ignacio, additional, Arnaout, Rand, additional, Arruda, Luisa Karla, additional, Asero, Riccardo, additional, Aygören‐Pürsün, Emel, additional, Banerji, Aleena, additional, Bauer, Andrea, additional, Ben‐Shoshan, Moshe, additional, Berardi, Alejandro, additional, Bernstein, Jonathan A., additional, Betschel, Stephen, additional, Bindslev‐Jensen, Carsten, additional, Bizjak, Mojca, additional, Boccon‐Gibod, Isabelle, additional, Bork, Konrad, additional, Bouillet, Laurence, additional, Boysen, Henrik Balle, additional, Brodszki, Nicholas, additional, Broesby‐Olsen, Sigurd, additional, Busse, Paula, additional, Buttgereit, Thomas, additional, Bygum, Anette, additional, Caballero, Teresa, additional, Campos, Régis A., additional, Cancian, Mauro, additional, Cherrez‐Ojeda, Ivan, additional, Cohn, Danny M., additional, Costa, Célia, additional, Craig, Timothy, additional, Criado, Paulo Ricardo, additional, Criado, Roberta F., additional, Csuka, Dorottya, additional, Dissemond, Joachim, additional, Du‐Thanh, Aurélie, additional, Ensina, Luis Felipe, additional, Ertaş, Ragıp, additional, Fabiani, José E., additional, Fantini, Claudio, additional, Farkas, Henriette, additional, Ferrucci, Silvia Mariel, additional, Figueras‐Nart, Ignasi, additional, Fili, Natalia L., additional, Fomina, Daria, additional, Fukunaga, Atsushi, additional, Gelincik, Asli, additional, Giménez‐Arnau, Ana, additional, Godse, Kiran, additional, Gompels, Mark, additional, Gonçalo, Margarida, additional, Gotua, Maia, additional, Gower, Richard, additional, Grumach, Anete S., additional, Guidos‐Fogelbach, Guillermo, additional, Hide, Michihiro, additional, Ilina, Natalia, additional, Inomata, Naoko, additional, Jakob, Thilo, additional, Josviack, Dario O., additional, Kang, Hye‐Ryun, additional, Kaplan, Allen, additional, Kasperska‐Zając, Alicja, additional, Katelaris, Constance, additional, Kessel, Aharon, additional, Kleinheinz, Andreas, additional, Kocatürk, Emek, additional, Košnik, Mitja, additional, Krasowska, Dorota, additional, Kulthanan, Kanokvalai, additional, Kumaran, M. Sendhil, additional, Larco Sousa, José Ignacio, additional, Longhurst, Hilary J., additional, Lumry, William, additional, MacGinnitie, Andrew, additional, Magerl, Markus, additional, Makris, Michael P., additional, Malbrán, Alejandro, additional, Marsland, Alexander, additional, Martinez‐Saguer, Inmaculada, additional, Medina, Iris V., additional, Meshkova, Raisa, additional, Metz, Martin, additional, Nasr, Iman, additional, Nicolay, Jan, additional, Nishigori, Chikako, additional, Ohsawa, Isao, additional, Özyurt, Kemal, additional, Papadopoulos, Nikolaos G., additional, Parisi, Claudio A. S., additional, Peter, Jonathan Grant, additional, Pfützner, Wolfgang, additional, Popov, Todor, additional, Prior, Nieves, additional, Ramon, German D., additional, Reich, Adam, additional, Reshef, Avner, additional, Riedl, Marc A., additional, Ritchie, Bruce, additional, Röckmann‐Helmbach, Heike, additional, Rudenko, Michael, additional, Salman, Andaç, additional, Sanchez‐Borges, Mario, additional, Schmid‐Grendelmeier, Peter, additional, Serpa, Faradiba S., additional, Serra‐Baldrich, Esther, additional, Sheikh, Farrukh R., additional, Smith, William, additional, Soria, Angèle, additional, Staubach, Petra, additional, Steiner, Urs C., additional, Stobiecki, Marcin, additional, Sussman, Gordon, additional, Tagka, Anna, additional, Thomsen, Simon Francis, additional, Treudler, Regina, additional, Valle, Solange, additional, van Doorn, Martijn, additional, Varga, Lilian, additional, Vázquez, Daniel O., additional, Wagner, Nicola, additional, Wang, Liangchun, additional, Weber‐Chrysochoou, Christina, additional, Ye, Young‐Min, additional, Zalewska‐Janowska, Anna, additional, Zanichelli, Andrea, additional, Zhao, Zuotao, additional, Zhi, Yuxiang, additional, Zuberbier, Torsten, additional, Zwiener, Ricardo D., additional, and Castaldo, Anthony, additional
- Published
- 2020
- Full Text
- View/download PDF
35. Anaphylactic reaction to (mixed) fruit juice containing dragon fruit
- Author
-
Kleinheinz, Andreas, Lepp, Ute, Hausen, Björn M., Petersen, Arnd, and Becker, Wolf-Meinhard
- Published
- 2009
36. In Memoriam Professor Dr. rer. nat. Björn Manfred Hausen – geboren am 11. 10. 1940 in Gotenhafen / Westpreußen, gestorben am 14. 12. 2017 in Stade
- Author
-
Geier, Johannes, primary and Kleinheinz, Andreas, additional
- Published
- 2018
- Full Text
- View/download PDF
37. 418 A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany.
- Author
-
Thaçi, Diamant, Kleinheinz, Andreas, Anastasiadou, Dimitra Maria, Stinson, John, and Armstrong, April W
- Subjects
- *
ATOPIC dermatitis , *ECZEMA , *COHORT analysis , *MONOCLONAL antibodies , *DUPILUMAB , *INTERLEUKIN-13 - Abstract
Tralokinumab is a high-affinity, fully human IgG4 monoclonal antibody that specifically inhibits interleukin-13 (IL-13), a key driver of atopic dermatitis (AD) disease progression. Clinical trials have shown that tralokinumab is efficacious in patients with moderate-to-severe AD and has a favorable safety profile, including a low frequency of adverse events (AEs) such as conjunctivitis. However, management of patients in routine clinical practice differ from those enrolled in clinical trials due to strict inclusion/exclusion criteria, and there is currently a lack of clinical data on tralokinumab use in the real-world setting. TRACE is an observational cohort study of patients with AD, which aims to better understand the effectiveness, safety and clinical use of tralokinumab in the real-world setting. This study aims to describe baseline characteristics and initial insights from the first 100 patients enrolled into TRACE in Germany. TRACE is a longitudinal, prospective, new user, noncomparative, observational, single-cohort study, with primary data collection of adult patients with AD who are treated with tralokinumab, according to national approved labels. The study is taking place across countries in Europe, North America and the Middle East. The primary objective is to assess changes in clinical signs and symptoms of AD in tralokinumab-treated patients. Secondary objectives are to investigate safety, quality of life, patient-reported outcomes and adherence, among others. This analysis includes the first 100 patients enrolled from 39 sites across Germany. Of the first 100 patients in TRACE initiated on tralokinumab in Germany, the majority were males. Most patients had moderate-to-severe disease as indicated by their mean Investigator's Global Assessment score and mean Eczema Area and Severity Index. Patients reported heavy symptomatic burden of disease, as demonstrated by their mean eczema-related sleep numerical rating scale (NRS) and mean worst daily pruritus NRS. Patients also reported a substantial impact on quality of life, as demonstrated by mean Dermatology Life Quality Index. Overall, approximately 4/5 of the patients were biologic-naïve. All biologic-experienced patients were previously treated with dupilumab, of whom most experienced one or more treatment failures. Reasons for switching from dupilumab included lack or loss of efficacy, and AEs, which included mainly conjunctivitis. Initial findings from the first 100 patients from TRACE in Germany showed that the majority of adult patients with moderate-to-severe AD treated with tralokinumab were biologic-naïve, indicating that tralokinumab is prescribed as first-line systemic treatment in the real world, in line with European Dermatology Forum guidelines. Of patients who switched from dupilumab, the main reasons for switching were lack or loss of efficacy, and conjunctivitis, indicating the need for an alternative biologic treatment such as tralokinumab. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany
- Author
-
Schmitt, Jochen, primary, Abraham, Susanne, additional, Trautmann, Freya, additional, Stephan, Victoria, additional, Fölster-Holst, Regina, additional, Homey, Bernhard, additional, Bieber, Thomas, additional, Novak, Natalija, additional, Sticherling, Michael, additional, Augustin, Matthias, additional, Kleinheinz, Andreas, additional, Elsner, Peter, additional, Weidinger, Stephan, additional, and Werfel, Thomas, additional
- Published
- 2016
- Full Text
- View/download PDF
39. S3-Leitlinie Allergieprävention — Update 2014
- Author
-
Schäfer, Torsten, primary, Bauer, Carl-Peter, additional, Beyer, Kirsten, additional, Bufe, Albrecht, additional, Friedrichs, Frank, additional, Gieler, Uwe, additional, Gronke, Gerald, additional, Hamelmann, Eckard, additional, Hellermann, Mechthild, additional, Kleinheinz, Andreas, additional, Klimek, Ludger, additional, Koletzko, Sibylle, additional, Kopp, Matthias, additional, Lau, Susanne, additional, Müsken, Horst, additional, Reese, Imke, additional, Schmidt, Sabine, additional, Schnadt, Sabine, additional, Sitter, Helmut, additional, Strömer, Klaus, additional, Vagts, Jennifer, additional, Vogelberg, Christian, additional, Wahn, Ulrich, additional, Werfel, Thomas, additional, Worm, Margitta, additional, and Muche-Borowski, Cathleen, additional
- Published
- 2014
- Full Text
- View/download PDF
40. S3-Leitlinie Allergieprävention — Update 2009
- Author
-
Muche-Borowski, Cathleen, primary, Kopp, Matthias, additional, Reese, Imke, additional, Sitter, Helmut, additional, Werfel, Thomas, additional, Schäfer, Torsten, additional, Beyer, Kirsten, additional, Friedrichs, Frank, additional, Hamelmann, Eckard, additional, Hellermann, Mechthild, additional, Huss-Marp, Johannes, additional, Kleinheinz, Andreas, additional, Lau, Susanne, additional, Rietschel, Ernst, additional, Rudack, Claudia, additional, Schmidt, Sabine, additional, Schnadt, Sabine, additional, and Schnitzer, Sylvia, additional
- Published
- 2009
- Full Text
- View/download PDF
41. Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5′-leader/gag region
- Author
-
Sczakiel, Georg, primary, Pawlita, Michael, additional, and Kleinheinz, Andreas, additional
- Published
- 1990
- Full Text
- View/download PDF
42. Blood transcriptome profiling identifies 2 candidate endotypes of atopic dermatitis
- Author
-
Möbus, Lena, Rodriguez, Elke, Harder, Inken, Boraczynski, Nicole, Szymczak, Silke, Hübenthal, Matthias, Stölzl, Dora, Gerdes, Sascha, Kleinheinz, Andreas, Abraham, Susanne, Heratizadeh, Annice, Handrick, Christiane, Haufe, Eva, Werfel, Thomas, Schmitt, Jochen, and Weidinger, Stephan
- Subjects
Adult ,Gene Expression Profiling ,Immunology ,eosinophil signatures ,Severity of Illness Index ,Dermatitis, Atopic ,blood transcriptome ,endotypes ,dupilumab ,gene expression ,Immunology and Allergy ,Humans ,RNA-Seq ,Interleukin-5 ,Transcriptome ,Atopic dermatitis - Abstract
Background Few studies have analyzed the bloodtranscriptomeinatopic dermatitis(AD). Objective We explored bloodtranscriptomicfeatures of moderate to severe AD. Methods Blood messengerRNA sequencingon 60 adults from the TREATgermany registry including 49 patients before and afterdupilumabtreatment, as well as from an independent cohort of 31 patients and 43 controls was performed. Patient clustering, differential expression, correlation and coexpression network analysis, and unsupervised learning were conducted. Results AD patients showed pronounced inflammatory expression signatures with increased myeloid and IL-5–related patterns, and clearly segregated into 2 distinct clusters, with striking differences in particular for transcripts involved ineosinophilsignaling. The eosinophil-highendotypeshowed a more pronounced global dysregulation, a positive correlation between disease activity and signatures related to IL-5 signaling, and strong correlations with several target proteins of antibodies or small molecules under development for AD. In contrast, the eosinophil-low endotype showed little transcriptomic dysregulation and no association between disease activity and gene expression. Clinical improvement with receipt of dupilumab was accompanied by a decrease ofinnate immune responsesand an increase of lymphocyte signatures including B-cell activation andnatural killer cellcomposition and/or function. The proportion of super responders was higher in the eosinophil-low endotype (32% vs 11%). Continued downregulation ofIL18RAP,IFNG,andgranzyme Ain the eosinophil-high endotype suggests a residual disturbance of natural killer cell function despite clinical improvement. Conclusion AD can be stratified intoeosinophilicand noneosinophilic endotypes; such stratification may be useful when assessing stratified trial designs and treatment strategies.
- Full Text
- View/download PDF
43. Dupilumab but not cyclosporine treatment shifts the microbiome toward a healthy skin flora in patients with moderate‐to‐severe atopic dermatitis
- Author
-
Hartmann, Jan, Moitinho‐Silva, Lucas, Sander, Nicole, Harder, Inken, Häsler, Robert, Rodriguez, Elke, Haufe, Eva, Kleinheinz, Andreas, Abraham, Susanne, Heratizadeh, Annice, Weisshaar, Elke, Schäkel, Knut, Handrick, Christiane, Augustin, Matthias, Wollenberg, Andreas, Staubach‐Renz, Petra, Ertner, Konstantin, Sticherling, Michael, Schwarz, Beate, Quist, Sven, Wiemers, Franca, Schenck, Florian, Wildberger, Julia, Tittmann, Lukas, Lieb, Wolfgang, Schmitt, Jochen, Werfel, Thomas, and Weidinger, Stephan
- Full Text
- View/download PDF
44. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine
- Subjects
medicine.medical_specialty ,Edema angioneuròtic ,Urticaria ,media_common.quotation_subject ,Immunology ,education ,GA2LEN ,Angioedema ,Center ,Excellence ,Management ,urticaria ,centres of reference and excelence ,immune system diseases ,center ,medicine ,Immunology and Allergy ,Center (algebra and category theory) ,Angioneurotic edema ,skin and connective tissue diseases ,media_common ,udc:616.1 ,business.industry ,angioedema ,humanities ,referenčni centri odličnosti ,Medicine ,Allergy ,Family medicine ,excellence ,medicine.symptom ,business ,Global Allergy and Asthma European Network ,Urticària ,management - Abstract
This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.
- Published
- 2020
45. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
- Author
-
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, and Röckmann H
- Abstract
Importance: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation., Objective: To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population., Design, Setting, and Participants: This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab., Main Outcomes and Measures: Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation., Results: In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness., Conclusion and Relevance: This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.
- Published
- 2024
- Full Text
- View/download PDF
46. Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
- Author
-
Weisshaar E, Bentz P, Haufe E, Heinrich L, Apfelbacher C, Heratizadeh A, Abraham S, Harder I, Kleinheinz A, Wollenberg A, Schäkel K, Wiemers F, Ertner K, Augustin M, Wildberger J, von Kiedrowski R, Worm M, Zink A, Effendy I, Asmussen A, Pawlak M, Sticherling M, Hilgers M, Handrick C, Quist S, Schwarz B, Bell M, Staubach-Renz P, Hong-Weldemann SH, Homey B, Bruecher J, Weidinger S, Werfel T, and Schmitt J
- Subjects
- Humans, Pruritus, Registries, Dermatitis, Atopic
- Abstract
Competing Interests: Conflicts of interest: J.S. is coprincipal investigator of TREATgermany and reports institutional grants for investigator-initiated research from the German GBA, the BMG, BMBF, EU, Federal State of Saxony, Novartis, Sanofi, ALK and Pfizer. He participated in advisory board meetings as a paid consultant for Sanofi, Lilly and ALK. K.S. received honoraria as an investigator, speaker’s honoraria and grants, and has been an advisor for the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Eli-Lilly, Galderma, Janssen, LEO Pharma, Merck Serono, Morphosys, Novartis, Pfizer, Regeneron, Sanofi and UCB Pharma. L.H. is a research associate of TREATgermany, which is an academic, investigator-initiated clinical registry that is financially supported by AbbVie GmbH & Co. KG, Galderma S. A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc. and Sanofi-Aventis Deutschland GmbH. S.A. has received lecture and/or consultancy fees from Novartis, LEO Pharma, Amgen, Lilly, Sanofi, Beiersdorf, Janssen, UCB and AbbVie. E.W. received consultancy fees from Sanofi/Genzyme and has participated in clinical trials for Galderma Ltd and TREVI Ltd.
- Published
- 2023
- Full Text
- View/download PDF
47. Wahrnehmung der Corona-Pandemie durch Neurodermitispatienten - Ergebnisse aus dem Neurodermitisregister TREATgermany.
- Author
-
Helmert C, Siegels D, Haufe E, Abraham S, Heratizadeh A, Kleinheinz A, Harder I, Schäkel K, Effendy I, Wollenberg A, Sticherling M, Stahl M, Worm M, Schwichtenberg U, Schwarz B, Rossbacher J, Buck PM, Schenck F, Werfel T, Weidinger S, and Schmitt J
- Published
- 2022
- Full Text
- View/download PDF
48. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
- Author
-
Schmitt J, Abraham S, Trautmann F, Stephan V, Fölster-Holst R, Homey B, Bieber T, Novak N, Sticherling M, Augustin M, Kleinheinz A, Elsner P, Weidinger S, and Werfel T
- Subjects
- Adult, Alitretinoin adverse effects, Alitretinoin therapeutic use, Anti-Inflammatory Agents adverse effects, Azathioprine adverse effects, Azathioprine therapeutic use, Cyclosporine adverse effects, Cyclosporine therapeutic use, Dermatitis, Atopic diagnosis, Female, Follow-Up Studies, Humans, Leflunomide adverse effects, Leflunomide therapeutic use, Long-Term Care, Male, Methotrexate adverse effects, Methotrexate therapeutic use, Mycophenolic Acid adverse effects, Mycophenolic Acid therapeutic use, Prednisolone adverse effects, Prednisolone therapeutic use, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Dermatitis, Atopic drug therapy, Registries
- Abstract
Background: The goal of clinical registries is to document the use and effectiveness of therapeutic interventions under real-life conditions. They are an indispensable prerequisite of evidence-based health care., Methods: Initiated in 2011, the German Atopic Dermatitis Registry TREATgermany is the first registry of patients with severe atopic dermatitis worldwide. Adults with severe atopic dermatitis (current/prior systemic antiinflammatory treatment and/or objective SCORAD ≥ 40) are prospectively followed over the course of 24 months. Employed treatment modalities are documented, and validated measuring tools are used to assess clinical disease severity (EASI, objective SCORAD), quality of life (DLQI), symptoms (POEM), global disease severity, as well as patient satisfaction. Herein, we describe the characteristics, therapeutic selection, and effectiveness of systemic antiinflammatory treatments of patients enrolled in the registry until October 2014., Results: Overall, 78 individuals (mean age 39 years, 61 % men) were enrolled at five recruitment centers. Patients frequently made use of inpatient and outpatient services. Not only was cyclosporine the most frequently administered systemic treatment, but also the most effective (EASI 50 response rate 51 %; EASI 75 response rate 34 % at 12 weeks). Azathioprine, methotrexate, oral prednisolone, mycophenolate, alitretinoin, and leflunomide were also used in some patients., Conclusions: The present analysis of the German Atopic Dermatitis Registry provides important data with respect to current medical care of adults with severe atopic dermatitis in Germany. It shows the high disease burden, the benefits of current treatment options, and the need for additional effective and safe long-term treatment options., (© 2016 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
49. Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitis-Registers TREATgermany.
- Author
-
Schmitt J, Abraham S, Trautmann F, Stephan V, Fölster-Holst R, Homey B, Bieber T, Novak N, Sticherling M, Augustin M, Kleinheinz A, Elsner P, Weidinger S, and Werfel T
- Abstract
Hintergrund: Versorgungsregister dienen der Erfassung des Einsatzes und der Wirksamkeit von Therapien unter realen Versorgungsbedingungen und sind als Basis einer evidenzbasierten Gesundheitsversorgung unverzichtbar., Methodik: Das deutsche Neurodermitis-Register TREATgermany wurde als weltweit erstes Register für Patienten mit schwerer Neurodermitis 2011 initiiert. Erwachsene mit schwerer Neurodermitis (aktuelle/frühere antientzündliche Systemtherapie und/oder objektiver SCORAD ≥ 40) werden über einen Zeitraum von 24 Monaten prospektiv beobachtet. Anhand validierter Erhebungsinstrumente werden die klinische Erkrankungsschwere (EASI, SCORAD), Lebensqualität (DLQI), Symptome, globale Erkrankungsschwere sowie die Patientenzufriedenheit erfasst und die durchgeführten Therapien dokumentiert. Die vorliegende Analyse beschreibt die Charakteristika, Therapiewahl und Wirksamkeit der eingesetzten antiinflammatorischen Systemtherapien der bis Oktober 2014 eingeschlossenen Patienten., Ergebnisse: An fünf Zentren wurden insgesamt 78 Patienten (Durchschnittsalter 39 Jahre, 61 % männlich) eingeschlossen. Bei den Patienten besteht eine hohe Inanspruchnahme ambulanter und stationärer Leistungen. Ciclosporin war das am häufigsten eingesetzte Systemtherapeutikum und zeigte die höchste klinische Effektivität (EASI-50-Ansprechrate 51 %; EASI-75-Ansprechrate 34 % nach zwölfwöchiger Therapie). Azathioprin, Methotrexat (MTX), Prednisolon oral, Mycophenolat, Alitretinoin und Leflunomid wurden ebenfalls bei einzelnen Patienten eingesetzt., Schlussfolgerungen: Die vorliegende Registerauswertung gibt wichtige Hinweise zur derzeitigen Versorgung von Erwachsenen mit schwerer Neurodermitis in Deutschland, dokumentiert die hohe Erkrankungslast, den Nutzen vorhandener Therapien und den Bedarf an weiteren, effektiven und in der Langzeitanwendung sicheren Therapieoptionen., (© 2017 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.